Alnylam Pharmaceuticals
ALNY
#625
Rank
ยฃ25.03 B
Marketcap
ยฃ194.11
Share price
1.06%
Change (1 day)
32.09%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -ยฃ0.15 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ2.09 Billion. In 2023 the company made an earning of -ยฃ0.25 Billion, an increase over its 2022 earnings that were of -ยฃ0.77 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -ยฃ0.15 Billion-41.44%
2023 -ยฃ0.25 Billion-67.84%
2022 -ยฃ0.77 Billion36.93%
2021 -ยฃ0.56 Billion-8.04%
2020 -ยฃ0.61 Billion-15.66%
2019 -ยฃ0.72 Billion12.23%
2018 -ยฃ0.65 Billion62.91%
2017 -ยฃ0.4 Billion17.78%
2016 -ยฃ0.34 Billion43.44%
2015 -ยฃ0.24 Billion60.69%
2014 -ยฃ0.15 Billion98.2%
2013 -ยฃ73.17 Million
2011 -ยฃ43.16 Million27.48%
2010 -ยฃ33.86 Million-10.92%
2009 -ยฃ38.01 Million95.77%
2008 -ยฃ19.42 Million
2006 -ยฃ31.1 Million-9.13%
2005 -ยฃ34.23 Million34.74%
2004 -ยฃ25.4 Million36.79%
2003 -ยฃ18.57 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ0.46 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.91 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.10 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ92.77 Million-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ32.57 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.02 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ5.83 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ0.33 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel